Rheumatoid Arthritis

Goldman's Cecil Medicine: Twenty Fourth Edition

Volumn 2, Issue , 2012, Pages 1681-1689

  O'Dell, James R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856814669     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1604-7.00272-4     Document Type: Chapter

References (25)

1. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007, 146:406-415.
2. O'Dell JR, Haire CE, Erickson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
4. Lipsky PE, Van der Heijde D, Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 243:1594-1602.
5. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 38:35-45.
6. Lee YH, Bae SC, Song GG The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011, [Epub ahead of print.].
7. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition. N Engl J Med 2005, 353:1114-1123.
8. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58:2968-2980.
9. McInnes IB, O'Dell JR State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010, 69:1898-1906. Review of pathophysiology and treatment.
10. Scott DL, Wolf F, Huizinga TW Rheumatoid arthritis. Lancet 2010, 376:1094-1108. Comprehensive review.
11. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794. Biologics are associated with significantly higher rates of adverse events and TB reactivation.
12. Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010, 152:456-464. W155-66. Anti-citrullinated peptide antibodies are useful for the early diagnosis of rheumatoid arthritis.
13. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008, 148:124-134. Combinations of biologic disease-modifying antirheumatic drugs plus methotrexate improve clinical response rates more than monotherapy, but no combination strategy is clearly superior to others.
14. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol 2006, 33:2398-2408. A review of the biologics for the treatment of rheumatoid arthritis.
15. Gaujoux-Viala C, Smolen JS, Landewé R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1004-1009. Recommends methotrexate over other disease-modifying antirheumatic drugs.
16. Lee YH, Woo JH, Choi SJ, et al. Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Scand J Rheumatol 2010, 39:271-278. Tacrolimus (1.5-3 mg/day) was effective in DMARD-resistant or -intolerant patients with active RA.
17. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis: a genomewide study. N Engl J Med 2007, 357:1199-1209. This SNP related to two genes associated with chronic inflammation increased the risk for anti-CCP-positive RA.
18. Ranganath UK, Furst DE Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007, 33:197-217. A practical review.
19. Raval A, Akhavan-Toyserkani G, Brinker A, et al. Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007, 147:699-702. The highest risks are in patients who have positive tuberculin skin tests, are immunocompromised, or come from countries where TB is endemic.
20. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986. In a case-control study, STAT4 was associated with a two-fold increased risk for SLE and a 60% increased risk for RA.
21. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784. Consensus guidelines.
22. Scott DL, Kingsley GH Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704-712. An excellent overview of tumor necrosis factor inhibitors for rheumatoid arthritis.
23. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010;1:CD008341. Golimumab is significantly more efficacious than placebo when used in combination with methotrexate.
24. Vliet Vlieland TP, van den Ende CH Nonpharmacological treatment of rheumatoid arthritis. Curr Opin Rheumatol 2011, 23:259-264. Review of exercise, physical activity, and self-management interventions.
25. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010, 363:1303-1312. In a phase 2 study, a Syk inhibitor at a dose of 100 mg twice daily or 150 mg once daily was significantly superior to placebo at 6 months.